Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives

The extracted text does not present a discrete Methods section or report a systematic search strategy. Instead, the paper is a narrative, integrative review that draws on a broad array of sources, including historical records, anthropological accounts, preclinical studies, clinical trials of macrodoses, online surveys and observational studies of microdosing, and recent placebo-controlled experiments. Rather than following a specified database-search and selection protocol, the authors synthesise findings across multiple evidence streams to explore similarities and differences between macrodosing and microdosing, and to situate microdosing within social and cultural contexts. Where individual studies are cited, their design types (preclinical animal work, online surveys, double-blind placebo-controlled trials, self-blinding protocols) are noted, but the paper does not report inclusion criteria, search dates, or formal risk-of-bias assessment for the literature surveyed. Given the narrative character of the review, emphasis is placed on integrating clinical data (including recent trials of macrodoses), naturalistic and self-report data on microdosing, and theoretical frameworks such as ‘‘set and setting’’ and placebo/meaning-response mechanisms to interpret the available evidence.

Macrodoses: Historical and contemporary clinical literature reviewed by the authors indicates that classical psychedelics administered in typical, perceptually altering doses have shown promising effects in several clinical indications, including depression, anxiety associated with terminal illness, alcohol and tobacco dependence, and obsessive–compulsive disorder. The review notes both early methodological weaknesses in some trials (for example, lack of controls or blinding) and the recent ‘‘psychedelic renaissance’’ of better-controlled research. Population studies are cited to argue that classical psychedelics carry low addiction potential, few long-term physiological harms compared with substances such as alcohol and tobacco, and no clear association with worse mental-health outcomes; some surveys even link lifetime psychedelic use with lower psychological distress and reduced criminal behaviour. Microdoses: The authors report that microdosing is underexplored compared with macrodosing. Anthropological evidence and historical anecdotes describe low-dose use in various cultures for diverse purposes, and the contemporary microdosing movement was popularised by James Fadiman’s dosing guides and media coverage, especially among technology-sector workers. Typical microdosing protocols are intermittent (often a 3-day cycle) to minimise tolerance, with users commonly taking sub-perceptual amounts that do not induce hallucinations. Tolerance is mentioned as developing within about three days for some psychedelics, whereas DMT may be less prone to tolerance due to rapid metabolism. Preclinical and observational findings: Preclinical microdose work is heterogeneous—reported effects range from anxiogenic to anxiolytic and antidepressant. Animal studies show sex-dependent effects (for example, male rats gaining weight while females do not, and female rats showing decreased dendritic spine density in one report). A study of 52 male rats found no evidence of abuse potential with repeated low-dose LSD. Naturalistic and online survey studies commonly report self-reported improvements in creativity, mood, cognition, sociability, and traits such as openness and wisdom; some surveys also report reduced distractibility and lowered depressive and stress symptoms at follow-up points. However, these studies are vulnerable to selection and expectancy biases. Experimental findings and null results: Controlled experiments provide mixed evidence. The first double-blind, placebo-controlled trial of microdosing reported no significant changes in perception, concentration or consciousness. A web-based prospective survey found that positive expectations predicted mental-health improvements. A placebo-controlled study using a self-blinding protocol detected no significant psychological differences between microdosing and placebo groups. Reported adverse or negative effects in some studies include dosing difficulties, physiological discomfort (temperature dysregulation, insomnia, appetite loss, headaches), increased anxiety, and legal and supply risks associated with obtaining substances of uncertain purity.

Kaypak and colleagues interpret the evidence as sharply contrasting: macrodose psychedelic-assisted interventions, when delivered in supportive, controlled contexts following screening, demonstrate substantial and sustained clinical effects with acceptable tolerability, whereas microdosing remains equivocal and under-studied. They note that recent systematic reviews and regulatory moves (for example, FDA breakthrough therapy status for psilocybin in treatment-resistant depression) underscore growing clinical optimism about larger-dose protocols. The authors place particular emphasis on contextual and expectancy effects. They revisit ‘‘set and setting’’—psychological state and environmental context—as central modulators of psychedelic effects and argue that placebo and meaning-response mechanisms may be especially relevant to microdosing because its effects can be subtle and ambiguous. The paper highlights evidence that cultural discourse, media hype and positivity bias among experienced users can amplify expectancies and shape subjective reports. Practical problems for microdosing research are also discussed: difficulties with blinding, variability in dose and substance purity in naturalistic studies, concomitant drug use, and lack of screening in many user-reported datasets. Ethical, legal and cultural implications are also examined. The authors warn against cultural appropriation and commercialization of indigenous plant practices, stress the principle of ‘‘do no harm’’ given psychological risks (acute distress, rare prolonged psychosis) and potential physiological risks such as 5-HT2B-mediated cardiac valvulopathy with repeated exposure. Legality constrains rigorous research and funnels many users to unregulated supplies, increasing health risks. At the same time, the review suggests microdosing may offer a lower-barrier, less-stigmatised entry point for some participants into psychedelic research, and that cross-cultural comparisons (legal versus illegal settings) could illuminate the role of cultural context. Finally, the authors call for more rigorous studies with adequate experimental designs, longer follow-up, and attention to contextual factors, including comparisons between psychedelic-naive and experienced participants. They recommend that future work address practical blinding issues and ethical concerns around enhancement, fairness and potential social competition arising from microdosing used for cognitive enhancement.

The authors conclude that classical psychedelics in typical (macrodose) regimens show promising clinical results across several conditions, but that formal evidence on microdosing is sparse and inconclusive. While abundant informal reports and some early studies suggest possible mood- and performance-enhancing effects, controlled trials to date are mixed and placebo effects may account for some reported benefits. Kaypak and Raz recommend rigorous, ethically attentive research with appropriate experimental designs and follow-up to determine the safety and efficacy of microdosing and to clarify its potential role as a gentler entry point into psychedelic research.